You are subscribed to one or more CDC code sets email subscription services. This message serves to inform you that information has recently been updated and is now available.
Web Site Publication Date: August 9, 2019
Release Notes: This release does not include updates for Vaccine Information Statement (VIS) codes and maps. A separate set of release notes and files are prepared for VIS code updates and will be distributed in a separate release cycle.
General Note regarding this release: Codes with “Last Update” dates after June 25, 2019 reflect changes and additions in this release and include the following code set updates:
1) CVX Code Updates:
- CVX Code Added: CVX 196 – “tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecified” has been added. This code adds an option to record administration of single dose adsorbed adult Td vaccine where the specific Lf formulation is not known. The other two single dose CVX codes previously available are highly specific and both indicate the Lf formulation. Important information related to this new CVX code includes:
- CVX 196 is mapped to Vaccine Group “Td”
- CPT 90714 – “Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use”. The mapping of this CPT code has been changed from CVX 139 to the new CVX 196.
- CVX Code Status Changed: CVX 139 Td(adult) unspecified formulation has been changed back to “inactive” as it represents a code that should only be used to document historic vaccines where the formulation is unknown.
- CVX Code to Vaccine Group correction: CVX 195 – “Diphtheria, Tetanus, Poliomyelitis adsorbed” was incorrectly associated to Vaccine Group “Td” in the June 25 Release. The Vaccine Group has been corrected to “DTAP”.
2) MVX Code Updates:
- MVX Code Added: MVX TVA – TEVA Pharmaceuticals USA. Important NDC mapping changes and information related to this new MVX code include NDCs which have been remapped to the new MVX “TVA” code:
- Unit of Sale 51285-138-50 and Units of Use 51285-174-02 and 51285-175-02 for “Adenovirus Type 4 and Type 7 Vaccine, Live KIT”.
- The above NDCs were previously mapped to MVX “BRR” – Barr Laboratories. BRR is an inactive MVX code. TEVA merged with Barr Laboratories in 2008 and now manufactures former Barr vaccine products.
3) CPT Code Updates:
- CPT Code and Mapping Removed: CPT 90689 - Influenza virus vaccine, quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25 mL dosage, for intramuscular use. This code was mapped to CVX Code 150 - Influenza, injectable, quadrivalent, preservative free in the June 25, 2019 release. It should be noted that currently there is no available U.S. NDC for the 0.25 mL formulation. After many questions regarding this CPT code, it has been decided that it will not be mapped to any CVX code until there is a U.S. vaccine formulation that matches this CPT’s specific description. CPT 90689 will no longer appear on the CPT to CVX file.
4) Tradename/Manufacturer Code Updates:
- New Product/Tradename Product Added: A second entry for Adenovirus types 4 and 7 has been added to replace the inactive product of the same name associated to Barr Laboratories MVX “BRR”. The new product is associated to the MVX “TVA” for TEVA Pharmaceuticals and CVX 143 "Adenovirus types 4 and 7".
5) NDC Code Updates:
- The following 2019/2020 influenza seasonal vaccine NDCs have been added:
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0219-20 | 33332-0219-21 |
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0319-01 | 33332-0319-02 |
Afluria Quadrivalent | Seqirus Pty Ltd. | 33332-0419-10 | 33332-0419-11 |
FLUAD | Seqirus, Inc. | 70461-0019-03 | 70461-0019-04 |
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0896-52 | 58160-0896-41 |
Flublok Quadrivalent | Sanofi Pasteur Inc. | 49281-0719-10 | 49281-0719-88 |
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0897-11 | 19515-0897-01 |
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0906-52 | 19515-0906-41 |
FLUZONE High-Dose | Sanofi Pasteur Inc. | 49281-0405-65 | 49281-0405-88 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0419-10 | 49281-0419-58 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0631-15 | 49281-0631-78 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0419-50 | 49281-0419-88 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0519-25 | 49281-0519-00 |
- The following 2018/2019 seasonal influenza vaccine NDCs have been retired:
Sale Proprietary Name | Sale Labeler | Sale NDC11 | Use NDC11 |
|---|
AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 33332-0318-01 | 33332-0318-02 |
AFLURIA QUADRIVALENT | Seqirus Pty Ltd | 33332-0418-10 | 33332-0418-11 |
FLUARIX QUADRIVALENT | GlaxoSmithKline Biologicals SA | 58160-0898-52 | 58160-0898-41 |
FLUAD | Seqirus, Inc. | 70461-0018-03 | 70461-0018-04 |
Flublok Quadrivalent | Sanofi Pasteur Inc. | 49281-0718-10 | 49281-0718-88 |
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0900-11 | 19515-0900-01 |
Flulaval Quadrivalent | ID Biomedical Corporation of Quebec | 19515-0909-52 | 19515-0909-41 |
FLUZONE High-Dose | Sanofi Pasteur Inc. | 49281-0403-65 | 49281-0403-88 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0418-10 | 49281-0418-58 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0418-50 | 49281-0418-88 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0518-25 | 49281-0518-00 |
FLUZONE QUADRIVALENT | Sanofi Pasteur Inc. | 49281-0629-15 | 49281-0629-78 |
